



Healthcare News and Deals - July 16th, 2025

1. Chai Discovery Raises \$400M Series C at \$3.8B Valuation – Led by Index Ventures with Kleiner Perkins, Sequoia, Bain Capital Ventures, Baillie Gifford and OpenAI to Scale Generative AI Molecular Design for Pharma Partners Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE)

Its latest model, Chai-3, improves antibody binding affinity and target success rates over prior versions. The platform is already deployed at major pharmaceutical companies including Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE), accelerating pre-clinical drug discovery by predicting and reprogramming molecular interactions with engineering-grade precision and speed. [Link](#)

2. Octozi Raises \$3M Seed Led by Surface Ventures (with Remarkable Ventures and Debiopharm's Venture Arm) to Deploy Agentic AI Across Clinical Trial Data Operations

Phase III trials, a published study showed Octozi boosted data-cleaning throughput roughly six-fold, cut reviewer error rates from 54.7% to 8.5%, and reduced false-positive queries fifteen-fold. An economic analysis estimated over \$5M in savings per oncology study by locking databases sooner and compressing timelines. [Link](#)

3. Pearl Health Banks \$110M (Andreessen Horowitz-Led Equity Plus Trinity Capital Credit Facility) to Build AI Agents and Predictive Insights for Medicare Providers

New capital funds its Performance Intelligence tool, offering a natural-language reasoning engine over cost, quality and utilization data, plus care-orchestration AI agents automating wellness-visit scheduling, post-discharge follow-ups and outreach. Now managing \$3.6B in annualized medical spend, Pearl is expanding into Medicare Advantage to enable earlier, tech-driven intervention for high-risk patients. [Link](#)

4. TJM Labs Reveals \$100M Raised Across Three Rounds (Series B Led by Elephant, with Arthur Ventures and Udata Partners) for Pharmacy-Native AI Agents Now Live in 450+ Pharmacies

Its AI agents automate prescription intake, refill processing, prior-authorization support and patient communication, processing over 500,000 pharmacy tasks daily. Its Dual-Expert Model pairs pharmacists with AI engineers on every deployment, aiming to reduce staff burnout and reallocate labor toward patient care rather than replacing clinical judgment. [Link](#)

5. Insilico Medicine (HKEX: 3696) and Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) Form Strategic Alliance Worth Up to \$2.5B Combining Pharma.AI Generative Discovery With Global Manufacturing

The proposed collaboration, potentially exceeding \$2.5B, pairs Insilico's Pharma.AI platform with Bora's development, manufacturing, quality and commercialization capabilities to pioneer an AI-native drug innovation model. Insilico will also help strengthen Bora's AI capabilities across manufacturing, supply chain and operations. [Link](#)

6. Klinik Raises \$24M Series A (Draper Associates, I2BF Global Ventures, Tau Ventures, Proofpoint Capital, Wicklow Capital) to Scale HIPAA-Compliant "Practice-in-a-Box" Provider Platform Across 12 Specialties

Founded in 2021, Klinik has expanded from behavioral health into 12 medical specialties. The capital will scale the platform across additional disciplines, expand operational support infrastructure and reduce administrative burdens for independent specialist practices, positioning it as digital infrastructure for provider enablement. [Link](#)

7. GE HealthCare (NASDAQ: GEHC) and Mayo Clinic Launch MI-BET Theranostics Study Using Data- and Imaging-Informed AI to Personalize Radioligand Therapy for Advanced Prostate Cancer

Stemming from their 2023 Strategic Radiology Research Alliance, the study uses GE HealthCare's StarGuide SPECT/CT technology with MIM Software's MIM LesionID Pro to track tumor response, integrating imaging data with blood-based biomarkers and clinical outcomes. Mayo is the first U.S. site investigating GE's next-generation StarGuide GX technology for faster, more precise tumor assessment. [Link](#)

8. WHO Joins the Linux Foundation's Open Health Stack Software Foundation – Backed by Google – to Advance Open, Standards-Based Digital Health and Verifiable AI, Including "AI Commons for Global Health"

The initiative includes AI Commons for Global Health, a model-agnostic space co-developed with WHO for building shared technical protocols, health-specific AI skills, and evaluation and benchmarking tools. This gives countries an auditable, interoperable route to adopt trustworthy AI grounded in WHO norms rather than fragmented, donor-dependent systems. [Link](#)

9. Insilico Medicine (HKEX: 3696) and Takeda Forge AI Drug Discovery Collaboration Worth Up to \$600M, Deploying Pharma.AI Generative Platform Across Takeda's Therapeutic Areas

Insilico leads AI-driven discovery while Takeda applies global development capabilities and receives exclusive worldwide rights to selected therapeutics. Insilico gets roughly \$60M in

initiation fees and near-term milestones, with the total deal potentially reaching \$600M plus tiered royalties. The partnership also supports Takeda's transition to an AI-native discovery model integrating automation, robotics and generative AI. [Link](#)

10. United Health Products (OTCQB: UEEC) Establishes Collaboration With NAMSA to Sponsor an FDA-Cleared Clinical Study of Its CelluSTAT Hemostatic Gauze

Consistent with a company proposal the FDA approved in March 2026 for a non-affiliated party to oversee the study, NAMSA will first seek an Investigational Device Exemption. Upon completion, UHP will hold exclusive right of reference to the data for a revised Premarket Approval application, allowing the study to proceed while UHP resolves an outstanding FDA Warning Letter. [Link](#)

11. OpenLoop Acquires AI Communication Platform Hey Revia to Extend Its Virtual-Care Technology Stack Amid Accelerating Digital Health M&A

Hey Revia had positioned its platform around improving how clinical teams communicate with patients at scale. The deal terms were undisclosed. It reflects a broader trend of health-tech acquirers plugging AI functionality into existing clinical workflows quickly to differentiate their virtual-care offerings. [Link](#)

12. FDA Grants Aurenar Breakthrough Device Designation for a Brain-Bleed (Intracranial Hemorrhage) Detection Device

Intracranial hemorrhage is among the most time-critical conditions in emergency medicine, where detection speed directly affects outcomes. The designation signals the FDA views the device as meaningfully advancing available options and places Aurenar on a faster path toward potential clearance. [Link](#)

13. Sharecare Builds AI Health-Navigation Tool "AskMD" on Amazon Web Services (Amazon; NASDAQ: AMZN) Using Amazon Bedrock Multi-Model Orchestration

AskMD helps users work through symptoms, understand insurance benefits, find providers and assess care options within a single interface. The approach positions Sharecare within the growing ecosystem of health-tech firms building on major cloud AI infrastructure rather than training proprietary models. [Link](#)

14. University of Florida Health Cancer Institute Wins \$3.4M NCI (National Cancer Institute) R01 Grant to Advance Stem Cell-Based Breast Cancer Prevention

The project evaluates tissue markers capturing stem cells in benign breast-biopsy samples from cancer-free women, examining associations with subsequent breast cancer risk and known risk factors. The goal is determining whether these markers can predict risk in women with benign biopsies, laying the foundation for stem cell-based breast cancer prevention approaches. [Link](#)

15. 410 Medical Secures Oversubscribed \$12M Financing Led by Orlando Health Ventures (with Hatteras, Ballad Health, OSF Healthcare, Tampa General) to Scale LifeFlow Resuscitation Device and Fund Next-Generation Infuser

Its LifeFlow product line – FDA-cleared in 2016 – helps clinicians rapidly deliver fluid and blood to patients with sepsis, hemorrhagic shock and other time-critical conditions. Used by 500+ hospitals and EMS agencies, LifeFlow has treated nearly 80,000 patients. The capital scales commercial operations and funds a next-generation infuser planned for 2027 addressing speed, portability and ease of use. [Link](#)

16. Cognify Health Raises Seed Funding Led by Game Changers Ventures to Build a Telehealth Concussion-Care Platform for Youth Sports (Backed by Doctors Tied to the Lakers, Chargers, USA Basketball and UCLA BrainSPORT)

Cognify connects families to a concussion specialist via telehealth within 24 hours, providing a full return-to-learn and return-to-play plan. It is built with doctors tied to the Lakers, Chargers, USA Basketball and UCLA BrainSPORT, with concussion care as the entry point for broader integrated youth-sports healthcare. [Link](#)

Events:

1. July 26 - 28 - Association for Health Care Resource and Materials Management (AHRMM) Conference Health Care Supply Chain - San Antonio, TX

The Association for Health Care Resource & Materials Management (AHRMM) is a professional membership group within the American Hospital Association, focused on health care supply chain and materials management. Its annual conference is a major gathering for supply chain professionals across hospitals, health systems, and industry.

2. September 17, 2026 - Bamberg Health / Southeast Healthcare Innovation Summit - Atlanta, GA

At the Southeast **Healthcare Innovation Summit**, we'll address critical conversations about health system optimization, digital transformation, artificial intelligence, cybersecurity, interoperability, rural healthcare access, population health, and strategic partnerships. We are dedicated to addressing unique regional challenges and unlocking opportunities to enhance healthcare delivery and management. ([Link](#))

